Latest News
Apr 15, 2016
Oxford Team Wins “Outstanding Paper Award”

Oxford, UK – 15 April 2016 – a University of Oxford spin-out company developing a new generation of ultrasound-based medical devices, today announced that members of the co-founding team and R&D team of OxSonics have won the 2016 “Jorge Heller Journal of Controlled Release Outstanding Paper Award”, which specifically recognizes major advances in the delivery of bioactives.

The award for the paper "Increasing the Density of Nanomedicines Improves Their Ultrasound-mediated Delivery to Tumours" will be presented during the CRS Award Ceremony at the 2016 CRS Annual Meeting in Seattle, Washington, U.S.A.

Professor Bob Carlisle is a co-founder of OxSonics and forms part of the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL) within the Institute of Biomedical Engineering, Oxford University.  A regular co-author on well-cited Journal of Controlled Release papers, he is honoured to receive the award on the team’s behalf.

Dr. Colin Story, Chief Executive Officer commented: “This award once again recognises the caliber of world-leading science emanating from the Institute of Biomedical Engineering. The authors of this award winning paper include not only two of our academic founders, Professors Carlisle and Coussios, but also members of the OxSonics R&D team who previously conducted their research within the Institute”. 

- ENDS -

 

About OxSonics Limited

OxSonics was established in July 2013 to develop and commercialise ground-breaking advancements in the field of therapeutic ultrasound invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics “SonoTran” drug delivery platform has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. SonoTran can be applied to any cancer drug. A major benefit of OxSonics’ technology is the ability to provide real-time on-screen feedback to the clinician as to where and when drug delivery is taking place. OxSonics is based in Oxford, UK. For more information please visit: www.oxsonics.com.

 

About The Institute of Biomedical Engineering

The Institute of Biomedical Engineering (IBME) is a research institute of the Department of Engineering Science, and located on the Old Road Campus of the University of Oxford in Headington. The IBME offers a world-class venue for biomedical engineering research and postgraduate research training where engineers and clinicians work together on addressing unmet needs in the prevention, early diagnosis and treatment of major diseases and conditions. The Institute’s core research missions are to develop novel medical devices, technology and systems capable of delivering substantial healthcare benefit, and to translate new engineering technologies into clinical practice. For more information please visit: www.ibme.ox.ac.uk.

   PDF Version
© OxSonics Ltd 2016